Jim Tananbaum’s Technology in Treatment of Mental Disorders
The growing technology has slowly provided a breakthrough to the mobile phone platform whereby, mobile phones are capable of integrating with other digital equipments in real time. Recent news from the patient diary announced that, Mindstrong Health secured $14million dollars in their series-A funding. Investors such as Forecast Capital, Optium Ventures, Arch Ventures and One Mind Brain Health Impact Fund aided in the raising of the funds. The project is stipulated to help in the improvement of methods of administering treatment to patients with brain ailments. Mindstrong is antisipated to introduce the use of technology in the enhancement of the methods of treatment and monitoring mental disorders using behavior cognition technology.
The sophisticated technology is insinuated to incorporate the use of behavior cognition whereby, physicians will be capable of accessing their patient’s brain patterns through their Smartphone’s. Additionally, the platform will provide information about cognition biomarkers and the mood of the patient. Further, the platform is articulated to be a powerful approach that will form a basis to the formation of other better inventions in mental health care. The Foresite CEO Jim Tananbaum asserted that, the new unmatched understanding of the critical challenges affecting the medical community treatment is a huge invention that will positively influence the medical community.
About Jim Tananbaum
Dr. Jim Tananbaum is the founder, chief architect, and CEO of Foresite Capital with a 25 year experience of healthcare and investment. Jim focuses on operational strategies and financial opportunities in the building of franchise healthcare businesses. In the last two decades, he has helped his healthcare franchises grow in all segments of the healthcare economy
According to Bloomberg, before founding Foresite, Tananbaum was a founding partner of Prospect Venture Partners 2 and 3. In addition, he was also the founder and CEO of Theravance company. During his career, Jim has invested in over ten companies such as Amira pharmaceuticals, Healtheon, Amerigroup, Jazz pharmaceuticals just to mention a few.
Jim’s career was natured at Yale University with BS/BSEE degrees he also earned an M.D and M.B.A from Harvard University. Later on, Jim furthered his studies at the Massachusetts Institute of Technology where he earned an M.S